Spac Litigation: How Disclosure Failures Become Investor Lawsuits

Material misrepresentations in SPAC litigation typically involve inflated revenue projections, overstated synergies, undisclosed regulatory risks, and false statements about the target company's business or competitive position. Material omissions involve facts that were known to the sponsor or target management at the time of the de-SPAC merger but were not disclosed to investors. Forward-looking statements are sometimes protected by the PSLRA's safe harbor, but the safe harbor does not protect statements made without a reasonable basis or known to be false when made. SPAC sponsors and target company executives facing securities fraud claims should immediately engage securities fraud counsel to evaluate whether the safe harbor applies and to develop a defense strategy.

Sponsors typically receive founder shares representing 20 percent of the SPAC's post-IPO equity at a nominal cost, creating a strong financial incentive to complete a merger even on terms that may not serve public shareholders' best interests. Plaintiffs allege that sponsors failed to disclose the magnitude of this conflict, that the merger target was selected to benefit the sponsor rather than public shareholders, and that the proxy statement did not adequately explain the economics of the sponsor's promote. SPAC sponsors facing conflict-of-interest allegations should immediately engage corporate fraud counsel to assess disclosure adequacy and evaluate defense options.

Revenue projections, EBITDA forecasts, and synergy estimates that later prove wildly inaccurate are a primary focus of SPAC securities class actions. Plaintiffs typically argue that the projections were unreasonable when made, that management had access to contrary data, and that the projections were included in the proxy statement to induce shareholders to approve the merger. Companies and sponsors named in a SPAC securities class action should immediately engage securities fraud class action counsel to challenge the adequacy of the pleadings and attack the inference of scienter.

SPAC shareholders have the right to redeem their shares at approximately the IPO price before the de-SPAC merger closes if they do not wish to participate in the merger. When a proxy statement omits material information about the target company's financial condition, undisclosed liabilities, or regulatory risks, shareholders cannot make an informed redemption decision. SPAC proxy statement disclosure failures can give rise to fiduciary duty claims and Section 14(a) claims under the Securities Exchange Act of 1934. Companies and boards with a pending de-SPAC merger should immediately engage disclosure statements counsel to review the adequacy of all material disclosures before the shareholder vote.

Every director and officer who signed the SPAC's registration statement or the merger proxy statement faces potential liability under Section 11 of the Securities Act of 1933 for any material misstatement or omission. Section 11 liability is strict: the plaintiff does not need to prove scienter, only that the registration statement contained a material misstatement or omission and that the plaintiff suffered a loss. The due diligence defense is available, but it requires proof that the director or officer conducted a reasonable investigation and had reasonable grounds to believe the statements were accurate. Directors and officers facing personal exposure in a SPAC litigation matter should immediately engage D&O and professional liability counsel to assess the scope of their individual liability and evaluate their D&O insurance coverage.

D&O insurance is the primary financial protection for directors and officers facing personal liability in SPAC litigation. SPAC D&O policies frequently contain exclusions for claims arising from the de-SPAC merger itself, meaning that the policy covering the SPAC may not cover claims arising after the merger closes. The combined company will typically need to obtain new D&O coverage, and coverage gaps can leave directors and officers personally exposed for significant periods. Directors and officers who are uncertain about their D&O coverage in connection with a pending or completed de-SPAC merger should immediately engage class action litigation counsel to evaluate coverage gaps and indemnification rights.

The SEC investigates SPAC transactions for disclosure failures in the SPAC IPO or de-SPAC proxy statement, accounting misstatements at the target company, and unregistered broker-dealer activity by SPAC sponsors who receive transaction-based compensation. SEC enforcement actions in SPAC cases can result in civil monetary penalties, disgorgement of ill-gotten gains, and injunctions against future securities law violations. DOJ involvement typically occurs when the underlying misconduct involves criminal securities fraud, wire fraud, or accounting fraud at the target company. Companies and individuals under SEC investigation for SPAC-related conduct should immediately engage SEC enforcement counsel to assess the scope of potential liability and manage the investigation response.

A Wells Notice is a written notification from the SEC staff that it intends to recommend an enforcement action. The recipient has the right to submit a Wells submission arguing why an enforcement action is not warranted. A well-prepared Wells submission can persuade the SEC staff to recommend no action or to recommend a significantly reduced charge. The decision whether to submit a Wells submission, and what to include in it, requires a thorough analysis of the underlying facts, the applicable legal standards, and the specific allegations in the Wells Notice. Companies and individuals who have received a Wells Notice or formal subpoena in a SPAC investigation should immediately engage SEC investigations counsel to respond strategically and protect their legal position.